IPO Plus

₹1.47

▼ -0.07 -4.55%

As of 11 Sept 2026 · delayed

BSE Listed

IBC
What does IBC mean?
BSE · Securities under IBCThe company is in the insolvency process. Practical meaning: equity holders often recover little or nothing in resolution, so the exchange restricts price movement to stop speculative churn in a claim that may be extinguished.Criteria: Company admitted to the Corporate Insolvency Resolution Process under the Insolvency & Bankruptcy Code; placed under surveillance with restricted price movement.Exchange notice · 2026-06-15

Evoq Remedies Limited (543500)

Volume: 72,000Avg Vol 1W: 36,800Avg Vol 1M: 37,45552W Range:₹1.47₹6.11
BSE www.evoqremedies.com AI Report
Key Ratios
Checked 6h ago
Market Cap₹24 Cr
Current Price₹1.47
Previous Close₹1.54
High / Low (52w)₹6.11 / ₹1.47
Volume72,000
Avg Vol (1W)36,800
Avg Vol (1M)37,455
Stock P/E314.67
Book Value₹18.56
Dividend Yield—
ROE—
ROA—
Revenue (TTM)—
Revenue Growth—
Profit Margin—
Total Debt—
Shares Outstanding—
Face Value—
EPS (TTM)—
P/B0.51
Debt / Equity0.06
50 DMA₹1.85
200 DMA₹2.77
Day change-4.55%
SurveillanceIBC
Price Chart
₹1.47▼ 60.05% · 1Y
₹6₹116.5L
2025-09-11
2026-09-11

20-day avg volume: 40K shares

Pros
  • Company is almost debt-free.
  • Revenue grew 125% YoY.
  • Stock trades below its book value.
Cons
  • Stock trades at a high P/E of 315.
Profit & Loss (Annual)
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹3 Cr₹9 Cr₹10 Cr₹17 Cr₹26 Cr₹6 Cr₹14 Cr
EBITDA₹0 Cr₹0 Cr₹1 Cr₹1 Cr₹2 Cr₹1 Cr₹0 Cr
Net Profit₹0 Cr₹0 Cr₹1 Cr₹1 Cr₹2 Cr₹0 Cr₹0 Cr
EPS0.1607150.71.190.330.04
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹2 Cr₹6 Cr₹8 Cr₹33 Cr₹35 Cr₹37 Cr₹50 Cr
Total Liabilities₹2 Cr₹6 Cr₹7 Cr₹10 Cr₹10 Cr₹12 Cr₹5 Cr
Equity₹0 Cr₹0 Cr₹1 Cr₹23 Cr₹25 Cr₹25 Cr₹45 Cr
Total Debt———————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹0 Cr₹-26 Cr₹-4 Cr₹5 Cr₹-15 Cr
Investing₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Financing₹0 Cr₹29 Cr₹1 Cr₹-5 Cr₹15 Cr
Free Cash Flow₹0 Cr₹-26 Cr₹-4 Cr₹5 Cr₹-15 Cr
Shareholding
Promoter 0.02% Institutions 0% Public 99.98%
Efficiency & Working Capital
ROCE—
Interest Coverage0
Dividend Payout—
Debtor Days268 d
Inventory Days69 d
Payable Days109 d
Cash Conversion Cycle228 d
Working Capital Days336 d
Shareholding Details

As of 2026-03-31

Promoter0%
FII0%
DII0%
Institutions0%
Public100%
Promoter Pledge0%
No. of Shareholders1,655
Shareholding Pattern

Quarterly — figures in %. Latest 11 quarters.

PeriodFeb 2022Mar 2022Sept 2022Mar 2023Sept 2023Mar 2024Jun 2024Sept 2024Mar 2025Sept 2025Mar 2026
Promoters100%73.5%73.5%73.5%73.5%20.5%11.2%11.2%11.2%11.2%0%
FIIs0%0%0%0%0%0%0%0%0%0%0%
DIIs0%0%0%0%0%0%0%0%0%0%0%
Public0%26.5%26.5%26.5%26.5%79.5%88.8%88.8%88.8%88.8%100%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders78247277077271,6721,5881,5771,7231,6791,655
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Dhruv GanjiPublic Shareholding11.4%28,25,000
Prashant SevantikarPublic Shareholding11.4%28,25,000
Surya Prakash JethliaPublic Shareholding2.6%6,52,000
Nilesh M SuhagiyaPublic Shareholding2.1%5,20,000
Anand MohanPublic Shareholding1.5%3,80,000
Yashiv Holdings Private LimitedPublic Shareholding1.5%3,64,000
Pattabiraman N RPublic Shareholding1.4%3,48,000
Gayathri RadhakrishnanPublic Shareholding1%2,60,000
Ambalal Karamshibhai SenghaniPublic Shareholding1%2,60,000
Bhumishth Narendrabhai PatelShareholding of Promoter and Promoter Group0%3,574
Narendrakumar Gangaramdas PatelShareholding of Promoter and Promoter Group0%71
Patel Payal BhumishthShareholding of Promoter and Promoter Group0%71
Sushilabahen Narendrakumar PatelShareholding of Promoter and Promoter Group0%71
Dahyabhai Mafatlal PatelShareholding of Promoter and Promoter Group0%71
Auxilia Pharmaceuticals Private LimitedShareholding of Promoter and Promoter Group0%71
Board of Directors
NameDesignationYear
Bhumishth Narendrabhai PatelExecutive Director & MD2025
Narendrakumar Gangaramdas PatelNon Executive Director2025
Harsh KothariIndependent Director2025
Aesha Harsh ShahIndependent Director2025
Pushpa JoshiIndependent Director2025
Nikita JainCompany Sec. & Compli. Officer2025
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10252525
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202500031623
20250003714
2025000077
Insider / Designated-Person Trades

3 recent disclosure(s)

Bhumishth Narendrabhai PatelDisposal · 5,36,000
Bhumishth Narendrabhai PatelDisposal · 7,52,000
Payal Bhumishth PatelDisposal · 14,40,000
Substantial Acquisitions (SAST)

3 disclosure(s)

Market21/10/2025 · 5,36,000
Market20/10/2025 · 7,52,000
Market17/10/2025 · 14,40,000
Company Information
Incorporated2010
AuditorH Thakkar & Co. LLP
Investor Email[email protected]
🌐 www.evoqremedies.com ↗

📍 F-12-A 1st Floor V R Complex, Nr.Sanathal Cross Road Santhal, Ahmedabad, Gujarat, 382210

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Ekennis Software Service Ltd.Gateway DistriparksGMR Power & Urban InfraBhatia Colour Chem LimitedMotherson Sumi WiringAchyut Healthcare LimitedVeranda Learning SolutionsSunrise Efficient Marketing Ltd.Dhyaani Tradeventtures LimitedHariom Pipe IndustriesEighty Jewellers LimitedShashwat Furnishing Solutions Ltd.All “54” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search

Telegram App